ストックスクリーナーアプリを入手
9.00
8.70%
0.72
プレマーケット:
9.40
0.40
+4.44%
前日終値:
$8.28
開ける：
$8.15
24時間の取引高:
43,112
Relative Volume:
0.45
時価総額：
$83.27M
収益：
-
当期純損益:
$-6.42M
株価収益率:
-1.6068
EPS:
-5.6013
ネットキャッシュフロー:
$-7.45M
1週間 パフォーマンス:
-9.46%
1か月 パフォーマンス:
+28.21%
6か月 パフォーマンス:
+20.32%
1年 パフォーマンス:
-7.22%
1日の値動き範囲:
$8.15
$9.02
1週間の範囲:
$7.80
$10.00
52週間の値動き範囲:
$1.80
$16.94
Cervomed Inc Stock (CRVO) Company Profile
CRVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.00 | 76.61M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-12-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-18 | 開始されました | Chardan Capital Markets | Buy |
| 2024-07-26 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cervomed Inc (CRVO) 最新ニュース
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed stock soars after promising dementia drug trial results - Investing.com
CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewswire Inc.
How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser
Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Update Report & Low Drawdown Investment Strategies - Newser
Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser
Why CervoMed Inc. (DP8) stock is a strong analyst pick2025 Volatility Report & Reliable Trade Execution Plans - Newser
CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus
CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus
Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com UK
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - Sahm
How CervoMed Inc. (DP8) stock gains from tech spending2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsShare Buyback & AI Powered Market Entry Ideas - Newser
What analyst consensus says on CervoMed Inc. stockRecession Risk & Free Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
CervoMed Inc. (CRVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - ADVFN
CervoMed Inc Stock Analysis and ForecastVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
CervoMed Inc. to Present Phase 2b Trial Results of Neflamapimod for Dementia with Lewy Bodies at CTAD Conference - Quiver Quantitative
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - Sahm
CervoMed Executives Make Bold Moves with Major Stock Purchases! - TipRanks
Will CervoMed Inc. stock outperform Nasdaq indexWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress - Quiver Quantitative
CervoMed Inc. stock retracement – recovery analysisChart Signals & Smart Money Movement Tracker - newser.com
Will CervoMed Inc. (DP8) stock deliver compounding returns2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO - Investing.com Australia
CervoMed CEO Alam buys shares worth $182,736 By Investing.com - Investing.com Australia
Elder William buys CervoMed (CRVO) stock worth $29,250 By Investing.com - Investing.com Canada
Insider Buying: Matthew Winton Acquires Additional Shares of Cer - GuruFocus
Gregoire Sylvie buys CervoMed (CRVO) shares worth $182,736 By Investing.com - Investing.com Canada
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO By Investing.com - Investing.com South Africa
Elder William buys CervoMed (CRVO) stock worth $29,250 - Investing.com
CervoMed CEO Alam buys shares worth $182,736 - Investing.com India
Tools to monitor CervoMed Inc. recovery probabilityJuly 2025 Recap & AI Based Trade Execution Alerts - newser.com
[Form 4] CervoMed Inc. Insider Trading Activity - Stock Titan
How to integrate CervoMed Inc. into portfolio analysis toolsMarket Growth Summary & Real-Time Chart Breakout Alerts - newser.com
CervoMed Inc. stock trend outlook and recovery pathTake Profit & Fast Exit/Entry Strategy Plans - newser.com
Cervomed Inc (CRVO) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):